The comparative effects of Itopride and Levosulpiride orally used in patients suffering from Non-ulcer dyspepsia
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20193202Keywords:
Efficacy, Itopride, Levosulpiride, Safety profile, TolerabilityAbstract
Background: Itopride and Levosulpiride both comes under the group of Prokinetic drugs. These drugs are used for the treatment of non-ulcer dyspepsia, heart burn, nausea and vomiting. Both drugs act on dopaminergic D2 receptor as antagonist and increases the concentration of acetylcholine so that gastric peristalsis will be increase and that time pressure at lower oesophageal sphincter will be increase thus gastric motility increases and there will be good gastro-duodenal co-ordination.
Method: This study has to conduct on patients with complains of non-ulcer dyspepsia attended Medical outdoor and department of pharmacology of SKMCH Muzaffarpur, Bihar, India. The total 60 patients have to include in the study, which have to randomly divide in two groups. Group A (itopride) comprising of 30 patients and Group B (Levosulpiride) comprising of 30 patients. Patients have to randomly allocate to receive one tablet of itopride hydrochloride, 50 mg three times daily before meal and one tablet Levosulpiride of 75 mg three times daily before meal. Authors have to enroll the patients at the interval of two weeks and continue it upto 3 months.
Results: Study did not found any remarkable change in biochemistry profile. Only QT prolongation changes were found in two patients, but no serious cardiac toxicity was observed with patient receiving Levosulpiride. Neither QT prolongation nor serious cardiac toxicity was observed with itopride hydrochloride therapy.
Conclusions: In present study, efficacy of Itopride was comparable to Levosulpiride in relieving the symptoms of non-ulcer dyspepsia. Both the drugs were clinically and biochemically well tolerated. QT prolongation changes were found in two patients, but no serious cardiac toxicity was observed with patient receiving Levosulpiride. Itopride does not show cardiac toxicity and any changes in ECG.
References
Dyspepsia at Dorland's Medical Dictionary.
Duvnjak, edited by Marko. Dyspepsia in clinical practice (1. Aufl. Ed.). New York: Springer; 2011:2.
Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol. 2005;100(10):2324-37.
Zajac P, Holbrook A, Super ME, Vogt M. An overview: current clinical guidelines for the evaluation, diagnosis, treatment, and management of dyspepsia. Osteopathic Fam Physician. 2013;5(2):79-85.
Ford AC, Moayyedi P. Dysepsia. BMJ. 2013;347:f 5059.
Iwanaga Y, Miyashita N, Saito T, Morikawa K, Itoh Z. Gastroprokinetic effect of a new benzamide derivative itopride and its action mechanisms in conscious dogs. Japanese J Pharmacol. 1996;71(2):129-37.
Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. 2006;354(8):832-40.
Huang X, Lv B, Zhang S, Fan YH, Meng LN. Itopride therapy for functional dyspepsia: a metaanalysis. World J Gastroenterol. 2012;18(48):7371-7.
Chey, William Y. Irritable Bowel Syndrome, An Issue of Gastroenterology Clinics-E-Book. Elsevier Health Sciences; 2011.
